The company purchases raw materials from the open market and seeks additional or replacement suppliers for single-source components to maintain production continuity. For the Genio system's implantable stimulator used in clinical and European commercial activities, subassemblies and components are sourced from external suppliers, with final assembly conducted in Belgium. For U.S. commercial activities, a third-party manufacturer in the United States is utilized. Manufacturing of the external parts of the Genio system is fully outsourced. In January 2026, the company announced a nine-year lease for a new cleanroom facility to expand manufacturing capacity, expected to be operational in 2027.
From November 2018 to early 2023, the company had a collaboration agreement with Cochlear Limited involving the development and commercialization of implantable treatments and support in manufacturing transfer projects. This collaboration has ended, and there are no current intellectual property licenses between the parties. The company is also part of a multiparty agreement with Man & Science SA, Cephalix SA, Glucobel SA, and Surgical Electronics SA concerning ownership and licensing of inventions related to implantable neurostimulators and medical indications. The company holds rights related to inventions for sleep disordered breathing.
Nyxoah Sa's Comment on Supply Chain
The company purchases raw materials from the open market and seeks additional or replacement suppliers for single-source components to maintain production continuity. For the Genio system's implantable stimulator used in clinical and European commercial activities, subassemblies and components are sourced from external suppliers, with final assembly conducted in Belgium. For U.S. commercial activities, a third-party manufacturer in the United States is utilized. Manufacturing of the external parts of the Genio system is fully outsourced. In January 2026, the company announced a nine-year lease for a new cleanroom facility to expand manufacturing capacity, expected to be operational in 2027.
From November 2018 to early 2023, the company had a collaboration agreement with Cochlear Limited involving the development and commercialization of implantable treatments and support in manufacturing transfer projects. This collaboration has ended, and there are no current intellectual property licenses between the parties. The company is also part of a multiparty agreement with Man & Science SA, Cephalix SA, Glucobel SA, and Surgical Electronics SA concerning ownership and licensing of inventions related to implantable neurostimulators and medical indications. The company holds rights related to inventions for sleep disordered breathing.
Sources:
Nyxoah Sa's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Nyxoah Sa’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
